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Summary
Relapse into drug taking among addicts often depends
on learned associations between drug-paired cues and
the rewarding effects of these drugs, such as cocaine
(COC). Memory for drug-paired cues resists extinc-
tion and contributes to the high rate of relapse; how-
ever, the molecular mechanisms underlying these
associations are not understood. We show that COC-
conditioned place preference (CPP) activates ERK,
CREB, Elk-1, and Fos in the nucleus accumbens core
(AcbC) but not shell. Intra-AcbC infusions of U0126,
an inhibitor of the ERK kinase MEK, prevent both the
activation of ERK, CREB, Elk-1, and Fos and retrieval
of COC-CPP. When tested again 24 hr or 14 days after
intra-AcbC infusions of U0126 or another MEK inhibi-
tor, PD98059, CPP retrieval and concomitant protein
activation were significantly attenuated. Together,
these findings indicate the necessity of the AcbC ERK
signaling pathway for drug-paired contextual cue
memories and suggest that these strong memories
can become susceptible to disruption by therapeutic
agents.
Introduction
Cocaine (COC) produces marked alterations in beha-
vior and mood in humans. Repeated intake increases
the likelihood of abuse of the drug, leading to the devel-
opment of addiction. Relapse into drug seeking in ad-
dicts often depends on the association formed be-
tween drug-paired cues and the rewarding effects of
the drug. A conditioned physiological response and
feelings of intense craving can occur when abstinent
drug abusers encounter cues predictive of drug avail-
ability (Childress et al., 1988). Memory for these drug-
paired cues is highly resistant to extinction and contrib-
utes to the high rate of relapse among addicts. One
animal model often used to study this contextual cue-
elicited COC craving is conditioned place preference
(CPP), in which rats learn to associate the rewarding
effects of COC with the environmental context in which
it is administered and later show a preference for that
environment.
The neural circuitry of cue-elicited drug seeking in-
volves several structures, including the basolateral
amygdala complex (BLC), prelimbic cortex (PrL), and
nucleus accumbens (Acb) (Weiss et al., 2000; Carelli
and Ijames, 2001). More recent studies have looked at
the differential contributions of the Acb’s two subre-*Correspondence: jfmarsha@uci.edugions, the core (AcbC) and shell (AcbSh), to this beha-
vior. The AcbSh appears to be involved in the rewarding
effects of drugs of abuse (Ito et al., 2004; Sellings and
Clarke, 2003), while the AcbC is required for maintain-
ing cue-elicited drug-seeking behavior (Fuchs et al.,
2004; Ito et al., 2004; Di Ciano and Everitt, 2004). Simi-
larly, we have reported increased numbers of cells ex-
pressing Fos, the protein product of the immediate-
early gene (IEG) c-fos, within the AcbC, but not AcbSh
following the expression of COC-CPP (Miller and Mar-
shall, 2005).
Despite knowledge of the neural circuitry and trans-
mitters underlying cue-elicited drug seeking, little is
known about the molecular mechanisms by which envi-
ronmental stimuli exert a motivational influence on
drug-seeking behavior. Recently, extracellular signal-
regulated kinase 1/2 (ERK) has been implicated in the
CNS effects of drugs of abuse. COC induces the phos-
phorylation of ERK (pERK) in the striatum (Valjent et
al., 2000). Administration of drugs that inhibit the ERK
kinase mitogen-activated protein kinase kinase (MEK)
blocks the establishment of CPP for COC and amphet-
amine (Valjent et al., 2000; Gerdjikov et al., 2004), as
well as cue-induced lever pressing for COC (Lu et al.,
2005). In addition, ERK has been implicated in synaptic
plasticity (English and Sweatt, 1996; Martin et al., 1997)
and learning, including fear conditioning and object
recognition (Atkins et al., 1998; Kelly et al., 2003). ERK
couples cell surface receptor-mediated alterations in
second messengers to long-term changes in gene ex-
pression through activation of two downstream tran-
scription factors, ets-like gene-1 (Elk-1) and, via the
intermediary Rsk2 (Roberson et al., 1999), cAMP re-
sponse element binding protein (CREB) (Cruzalegui et
al., 1999; Impey et al., 1998), which can then lead to
transcription of IEGs, including c-fos (Janknecht et al.,
1993; Mayr et al., 2001). These findings suggest that
ERK, CREB, and Elk-1 may be candidates for involve-
ment in the storage and retrieval of memories for COC-
associated contextual cues.
In this study, we trained animals in a CPP apparatus
to associate one chamber with COC. Animals were later
tested for their place preference in a drug-free state
and sacrificed to assess pERK, pCREB, and pElk-1 ac-
tivation using immunocytochemistry (ICC) and Western
blot analysis. To assess ERK’s involvement in retrieval
of the CPP memory, another group of animals received
intra-AcbC infusions of U0126, an inhibitor of MEK,
30 min before CPP testing. These animals were then
perfused to assess pERK, pCREB, pElk-1, and Fos
levels within the AcbC. To test for an enduring effect of
acute ERK inhibition, we assessed the effects of U0126
or another MEK inhibitor, PD98059, on reconsolidation
of memory for the drug-paired environment. The re-
consolidation hypothesis states that memories, when
retrieved, can become labile and susceptible to dis-
ruption. Animals were given either pre- or posttest in-
tra-AcbC infusions of U0126 and then tested again 24
hr or 14 days later. pERK, pCREB, pElk-1, and Fos
levels were again assessed within the AcbC.
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874Figure 1. Quantification of pERK, pCREB, and pElk-1 following COC-CPP Expression
(A) COC-CPP expression indicated by time spent in COC-paired compartment for drug-paired (n = 9) and drug-unpaired animals (n = 10) at
the initial and final tests. *Wilcoxon tests, p < 0.05. (B) Quantification of pERK, pCREB, and pElk-1 in AcbC and AcbSh. *Student’s t tests,
p < 0.05. Black areas in coronal section inset (Paxinos and Watson, 1998) indicate region of AcbC (left side) and AcbSh (right side) in which
cell counts were sampled. (C–H) AcbC pERK (C and F), pCREB (D and G), and pElk-1 (E and H) immunoreactivity in drug-paired (C–E) and
unpaired (F–H) animals. A more stringent criterion was applied to pCREB-ir quantification. Scale bar, 200 m. Error bars denote SEM.The results of these experiments demonstrate sev-
eral ways in which the AcbC ERK pathway is important
in memory for COC-associated contextual cues. First,
animals expressing COC-CPP showed activation of the
ERK pathway in the Acb core, but not shell. Second,
inhibition of AcbC ERK phosphorylation blocked the re-
trieval of COC-CPP. Third, when AcbC ERK phosphory-
lation was blocked immediately after retrieval, both
preference for the COC-associated chamber and re-
trieval-dependent protein activation were disrupted for
at least 2 weeks. These findings demonstrate the ne-
cessity of the AcbC ERK signaling pathway for drug-
paired contextual cue memory and prompt the thera-
peutically significant conclusion that these strong
memories can become susceptible to disruption.
Results
Acb ERK, CREB, and Elk-1 Activation
following COC-CPP Expression
Following CPP behavioral conditioning, drug-paired
animals showed an increase from baseline (“initial
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pest”) in the amount of time spent in the COC-paired
ompartment, whereas drug-unpaired animals did not
Figure 1A). There was a significant group by test in-
eraction [F(1, 17) = 8.62; p < 0.01], and drug-paired but
ot unpaired controls spent significantly more time in
he COC-paired compartment during the final, com-
ared to the initial test (Wilcoxon tests, drug-paired: z =
2.31, p < 0.05; unpaired: z = −0.97, p > 0.05). These
indings demonstrate the development of a preference
or the environment previously paired with COC.
Following CPP testing, pERK, pCREB, and pElk-1 im-
unoreactivity was examined in the AcbC and AcbSh
Figure 1B). For each, a significant group by region in-
eraction was observed [pERK: F(1, 14) = 5.09, p < 0.05;
CREB: F(1, 16) = 13.88, p < 0.01; pElk-1: F(1, 16) =
.89, p < 0.05], indicating that the drug pairing affected
rotein activation in the AcbC and AcbSh differently.
ignificantly greater numbers of cells immunoreactive
-ir) for each phosphoprotein were found in the AcbC,
ut not AcbSh, of drug-paired animals compared to
ontrols (Student’s t tests; AcbC pERK: t15 = 2.92,
CREB: t = 2.65, pElk-1: t = 3.27; ps < 0.05; AcbSh18 16
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875Figure 2. Western Blot Analysis of pERK1 and -2, pCREB, and pElk-1 following COC-CPP Expression
(A) COC-CPP expression indicated by time spent in COC-paired compartment by drug-paired (n = 8) and drug-unpaired animals (n = 8) at
the initial and final tests. *Wilcoxon tests, p < 0.05. Behavior in subsequent graphs will be depicted as a Difference Score (Final − Initial time
spent in COC-paired compartment). (B) Western blot analysis of pERK1 and -2, pCREB, and pElk-1 relative to total ERK1 and -2, CREB, and
Elk-1 protein levels in AcbC and AcbSh of drug-paired and unpaired animals. *Student’s t tests, p < 0.05. Black circles in coronal section
inset indicate location of AcbC (left side) and AcbSh (right side) tissue punches. (C–E) Representative blots of pERK1 and 2 bands and
corresponding ERK1 and -2 and cyclophilin bands (C), pCREB bands and corresponding CREB and cyclophilin bands (D), and pElk-1 bands
and corresponding Elk-1 and cyclophilin bands (E) from AcbC tissue of drug-paired and unpaired animals. Error bars denote SEM.pERK: t14 = 0.08, pCREB: t16 = −1.70, pElk-1: t17 =
−0.45; ps > 0.05; Figures 1B–1H).
Another group of animals used for Western blotting
also underwent CPP conditioning. Drug-paired animals
showed an increase from baseline in the amount of time
spent in the COC-paired compartment, while drug-
unpaired animals did not (Figure 2A). There was a sig-
nificant group by test interaction [F(1, 14) = 21.78; p <
0.001], and drug-paired but not unpaired controls,
showed a significant increase in the amount of time
spent in the COC-paired compartment (drug-paired: z =
−2.52, p < 0.05; unpaired: z = −0.70, p > 0.05).
Western blot analysis, used to confirm the ICC re-
sults, revealed no group differences in total ERK1,
ERK2, CREB, or Elk-1 in the AcbC or AcbSh [respec-
tively, F(1, 14) = 0.47, F(1, 14) = 0.63, F(1, 14) = 2.45,
F(1, 14) = 1.17; ps > 0.05]. A significant group by region
interaction was observed when levels of phosphory-
lated ERK2, CREB, and Elk-1 were expressed relative
to their respective total proteins [respectively, F(1, 14) =
6.84, F(1, 14) = 12.37, F(1, 14) = 7.08; ps < 0.05; Figures
2B–2E]. No such differences were observed for ERK1
[F(1, 14) = 0.004; p > 0.05]. Levels of all three phospho-
proteins increased in the AcbC, but not AcbSh, of drug-
paired animals compared to controls (AcbC pERK2:
t14 = 3.61, pCREB: t14 = 2.87, pElk-1: t14 = 2.68; ps <
0.05; AcbSh pERK2: t14 = 0.20, pCREB: t14 = −1.28,
pElk-1: t14 = 0.70; ps > 0.05).
Data from Western blotting were also analyzed by
using cyclophilin as a loading control protein for each
gel. No differences were observed in cyclophilin bands
of drug-paired and unpaired controls on the gelsloaded with tissue from either AcbC or AcbSh [respec-
tively, ERK gels: F(1, 14) = 0.55, F(1, 14) = 0.01; CREB
gels: F(1, 14) = 2.43, F(1, 14) = 0.43; Elk-1 gels: F(1,
14) = 1.48, F(1, 14) = 0.58; ps > 0.05]. Furthermore, when
levels of phosphorylated ERK2, CREB, and Elk-1 were
expressed relative to levels of cyclophilin, a significant
group by region interaction was again observed for
each phosphoprotein [ERK2: F(1, 14) = 4.66, p < 0.05;
CREB: F(1, 14) = 9.17, p < 0.01; Elk-1: F(1, 14) = 7.88,
p < 0.05], while no differences were observed for ERK1
[F(1, 14) = 0.59; p > 0.05].
Taken together, these results establish that CPP ex-
pression induces phosphorylation of ERK, CREB and
Elk-1 and that this activation is specific to the core of
the Acb. Because only the AcbC showed increased
levels of all three phosphoproteins, subsequent experi-
ments targeted the ERK signaling pathway in this
brain area.
Effect of MEK Inhibition within the AcbC
on Retrieval of COC-CPP
To assess ERK’s involvement in memory retrieval, an-
other group of animals was trained on CPP and re-
ceived intra-AcbC infusions of the MEK inhibitor U0126
30 min before CPP testing. Figure 3 depicts the location
of cannula tips in the AcbC for animals used in this and
subsequent experiments. After testing, animals were
perfused to assess numbers of pERK, pCREB-, pElk-1-,
and Fos-ir cells within the AcbC.
All animals received COC pairings during CPP train-
ing. There were no behavioral differences between ve-
hicle (veh)- and saline (sal)-infused animals [F(1, 14) =
Neuron
876Figure 3. Location of Needle Tips for All Intra-AcbC Infusions
Diagram represents histology from 132 animals whose behavioral
and molecular data are depicted in Figures 4–7. Because of the
extensive overlap between the infusion needle tips of these ani-
mals, not all tip locations are resolvable on this diagram.0.00; p > 0.05]; therefore, these groups were collapsed
into one control group. When the control and U0126-
infused groups were compared, a significant group by
test interaction was observed for the amount of time
spent in the COC-paired compartment [F(1, 31) = 9.01;
p < 0.01]. When the time spent in the COC-paired com-
partment at the initial test was subtracted from the
time spent in the compartment in the final test to yield
a difference score, a one-way analysis of variance
(ANOVA) revealed that animals infused with veh or sal
showed a significantly greater increase from baseline
in time spent in the COC-paired compartment, com-
pared to U0126-infused animals [F(1, 31) = 5.78; p <
0.05; Figure 4A]. One-way ANOVAs were used to assess
possible nonspecific motoric effects of the MEK inhibi-
tor. We found that intra-AcbC U0216 infusions had no
effect on two common measures of motor behavior
[rears: F(1, 31) = 2.42, crossings: F(1, 31) = 1.34; ps >
0.05] in the CPP apparatus (Figure 4B).
These findings demonstrate that the MEK inhibitor
blocked the expression of a preference for the environ-
ment previously paired with COC without influencing
measures of exploration in the test apparatus.
Effect of MEK Inhibition within the AcbC on pERK,
pCREB, pElk-1, and Fos Levels following Retrieval
Because veh- and sal-infused animals showed no dif-
ferences in numbers of AcbC pERK, pCREB, pElk-1, or
Fos-ir cells [respectively, F(1, 14) = 1.21, F(1, 14) = 0.04,
F(1, 14) = 0.53, F(1, 14) = 0.10; ps > 0.05], their data
were collapsed into one control group. In animals given
intra-AcbC infusions and tested for retrieval, U0126
strongly and significantly attenuated the induction of
pERK, pCREB, pElk-1, and Fos [respectively, F(1, 31) =
115.41, F(1, 31) = 119.22, F(1, 31) = 30.22, F(1, 31) =
142.96; ps < 0.001] in the AcbC compared to the control
animals (Figure 4C). Therefore, ERK activation appears
to be necessary for much of the activation of CREB and
Elk-1 and the Fos induction in the AcbC effected by
exposure to drug-paired cues. Further, these data sug-
gest that the MEK inhibitor blocked CPP expression by
preventing activation of the ERK signaling pathway.
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migure 4. Effect of Intra-AcbC U0126 Infusions on COC-CPP Re-
rieval and Concomitant Protein Activation
A) Change in time spent in the COC-paired compartment from the
nitial to the final test (Difference Score) for veh-infused (n = 10),
al-infused (n = 6), and U0126-infused (n = 17) animals. Data from
eh- and sal-infused animals collapsed into a single group (n =
6). *One-way ANOVA, p < 0.05. (B) Effect of the intra-AcbC U0126
nfusions on locomotor activity during the COC-CPP test, starting
0 min after the infusion. (C) Quantification of AcbC pERK, pCREB,
Elk-1, and Fos following the COC-CPP retrieval test. *One-way
NOVAs, p < 0.001. Error bars denote SEM.To examine the anatomic specificity of the intra-
cbC infusions, the numbers of pERK-ir cells were also
ounted in the AcbSh of veh- and U0126-infused ani-
als following retrieval. In contrast to the U0126-induced
ecrease in pERK-ir in the AcbC described above, no dif-
erence in pERK-ir was observed in the AcbSh of veh-
nd U0126-infused animals [Veh: 13.17 ± 3.6; U0126:
6.26 ± 6.9; F(31) = 2.42; p > 0.05]. These results sug-
est that there was little, if any, spread of the MEK in-
ibitor beyond the AcbC.
ffect of MEK Inhibition within the AcbC
n Reconsolidation of COC-CPP
o test for a lasting effect of acute ERK inhibition, we
ssessed its effect on reconsolidation of memory for
he drug-paired environment 24 hr later. For this experi-
ent, all animals received COC pairings during CPP
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877Figure 5. Effect of Intra-AcbC U0126 Infusions on COC-CPP Re-
consolidation and Concomitant Protein Activation
(A) Diagram outlines behavioral procedures for each group on test
days 1 and 2 (Veh-no test: n = 6; U0126-no test: n = 7; Veh-pretest:
n = 11; U0126-pretest: n = 10; Veh-posttest: n = 8; U0126-posttest:
n = 8). (B) Change in time spent in the COC-paired compartment
(Difference Score) from the initial to the test day 1 (*Student’s t
tests, differs from Veh-pretest, p < 0.01) and test day 2 (Student’s t
tests, *differs from Veh-pretest, #differs from Veh-posttest, ps <
0.01). (C) Quantification of AcbC pERK, pCREB, pElk-1, and Fos
(Student’s t tests, *differs from Veh-pretest, #differs from Veh-post-
test, ps < 0.001) following COC-CPP reconsolidation test. Error
bars denote SEM.training and, 48 hr later, received intra-AcbC infusions
of U0126, veh, or sal before or after CPP testing (test
day 1). These same animals were tested again 24 hr
later (test day 2). Numbers of AcbC pERK-, pCREB-,
pElk-1- and Fos-ir cells were counted following test day
2. Three treatment conditions were compared (Figure
5A). On test day 1, animals were (1) infused 30 min prior
to CPP testing (Veh-pretest and U0126-pretest), (2) in-
fused immediately after CPP testing (Veh-posttest and
U0126-posttest), or (3) infused and returned to their
home cages without a CPP test (Veh-no test and
U0126-no test). Analysis of the test day 1 CPP scores
revealed a drug by infusion time interaction [F(1, 36) =
6.68; p < 0.05]. Replicating the previous experiment’s
findings (Figure 4A), Veh-pretest animals displayed nor-mal CPP, while U0126-pretest animals did not (t19 =
−3.40; p < 0.01; Figure 5B). Because their infusions
were given after the CPP test, both Veh-posttest and
U0126-posttest animals displayed normal CPP on test
day 1 (t14 = 0.87; p > 0.05; Figure 5B).
On test day 2, all animals were tested again but were
not infused. A significant interaction was observed be-
tween drug treatment and infusion time [F(2, 44) = 3.43;
p < 0.05]. Orthogonal comparisons used to analyze the
effect of infusion time revealed that the test day 2 CPP
scores of groups given a pretest or a posttest infusion
on test day 1 did not differ from each other [F(1, 44) =
0.88; p > 0.05] but were significantly lower than those
of the groups not tested after their test day 1 infusion
[F(1, 44) = 6.58; p < 0.05]. Further analysis revealed that
both the Veh-no test and U0126-no test groups showed
equivalent, strong CPP on test day 2 (t11 = −0.19; p >
0.05), indicating that the MEK inhibitor had cleared from
the AcbC over the preceding 24 hr. Surprisingly, the ani-
mals that received U0126 infusions at the time of mem-
ory retrieval on test day 1 (U0126-pretest and U0126-
posttest) failed to show CPP on test day 2 relative to
their veh-treated counterparts (respectively, t19 = 3.44,
t14 = 3.10; ps < 0.01; Figure 5B).
To confirm these findings, the reconsolidation experi-
ment was repeated using a different MEK inhibitor,
PD98059. All animals received COC pairings during
CPP training and, 48 hr later, received intra-AcbC infu-
sions of PD98059 (PD98059-posttest) or veh (Veh-post-
test) immediately after CPP testing. Animals were
tested again 24 hr later without an infusion. Numbers
of AcbC pERK-, pCREB-, pElk-1-, and Fos-ir cells were
also counted following the day 2 test.
A significant interaction was observed between drug
treatment and test day [F(1, 20) = 10.59; p < 0.01]. The
Veh-posttest and PD98059-posttest animals displayed
equivalent, strong CPP on test day 1 (t20 = −0.09; p >
0.05; Figure 6A). While the CPP memory of the Veh-
posttest group was still intact on test day 2, the animals
of the PD98059-posttest group failed to express a pref-
erence (t20 = −4.45, p < 0.001; Figure 6A).
These results demonstrate that both MEK inhibitors,
U0126 and PD98059, are able to impair memory 24 hr
after their intra-AcbC infusion if the infusion is coupled
with a retrieval test on day 1.
Because of evidence suggesting that drug-induced
interference with reconsolidation of fear conditioning
may fade at longer drug-retest intervals (Lattal and
Abel, 2004), we repeated the experiment but delayed
the second CPP test for 14 days. The first CPP retrieval
test (test day 1) was immediately followed by intra-
AcbC infusions of U0126 (U0126-posttest) or veh (Veh-
posttest). The animals were returned to their home
cages for 14 days before being given a second test (test
day 15). Numbers of AcbC pERK-, pCREB-, pElk-1-, and
Fos-ir cells were also counted following the day 15 test.
A significant interaction was observed between drug
treatment and test day [F(1, 25) = 30.23; p < 0.001; Fig-
ure 7A]. Both Veh-posttest and U0126-posttest animals
displayed equivalent, strong CPP on test day 1 (t25 =
0.24; p > 0.05; Figure 7A). Although the place prefer-
ence memory of the Veh-posttest group was still intact
on test day 15, it was abolished in the U0126-posttest
animals (t = −3.31; p < 0.01; Figure 7A).25
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878Figure 6. Effect of Intra-AcbC PD98059 Infusions on COC-CPP Re-
consolidation and Concomitant Protein Activation
(A) Test day 1 and 2 difference scores (*Student’s t tests, p < 0.001)
in veh-infused (n = 11) and PD98059-infused (n = 11) animals. (B)
Quantification of AcbC pERK, pCREB, pElk-1, and Fos (*One-way
ANOVAs, p < 0.001) following COC-CPP reconsolidation test. Error
bars denote SEM.
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aThese findings suggest that (1) retrieved memories,
not simply established memories, are susceptible to
disruption by MEK inhibition when it is active during or
immediately after retrieval, and (2) this effect lasts at
least 2 weeks.
Effect of MEK Inhibition within the AcbC
on pERK, pCREB, pElk-1, and Fos Levels
following Test of Reconsolidation
Animals that received MEK inhibitor infusions at the
time of memory retrieval on test day 1 (U0126-pretest,
U0126-posttest, and PD98059-posttest) showed a sig-
nificant attenuation of pERK, pCREB, pElk-1, and Fos-
ir relative to all other groups when assayed after CPP
testing on test day 2 or 15.
For the results depicted in Figure 5C (U0126 infu-
sions, test day 2), a significant interaction between
drug treatment and infusion time was observed for all
four proteins [pERK: F(2, 44) = 17.09, pCREB: F(2, 44) =
18.59, pElk-1: F(2, 42) = 36.83, Fos: F(2, 43) = 11.37;
ps < 0.001]. AcbC protein levels in the U0126-pretest
and U0126-posttest groups did not differ from each
other on test day 2 [pERK: F(1, 44) = 3.27, pCREB: F(1,
44) = 0.75, pElk-1: F(1, 44) = 3.15, Fos: F(1, 44) = 0.36;
ps > 0.05]. However, protein levels of both groups were
significantly lower than those of the groups that did not
have a test coupled with their infusion on test day 1
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pveh-no test, U0126-no test; pERK: F(1, 44) = 58.20,
CREB: F(1, 44) = 18.33, pElk-1: F(1, 44) = 26.16, Fos:
(1, 44) = 24.90; ps < 0.001]. Further analysis revealed
hat the Veh-no test and U0126-no test groups did not
iffer in their strong protein activation in the AcbC
pERK: t11 = 0.04, pCREB: t11 = −0.34, pElk-1: t11 = 0.45,
os: t11 = 0.66; ps > 0.05). Animals that received U0126
nfusions at the time of memory retrieval on test day 1
U0126-pretest and U0126-posttest) showed a signifi-
ant attenuation of protein activation on test day 2 rela-
ive to their veh-treated counterparts (respectively,
ERK: t19 = 7.43, pCREB: t19 = 9.78, pElk-1: t19 = 11.31,
os: t19 = 8.78; pERK: t14 = 12.11, pCREB: t14 = 6.25,
Elk-1: t14 = 13.55, Fos: t14 = 5.12; ps < 0.001; Figure 5C).
Similarly, the levels of the PD98059-posttest group’s
rotein immunoreactivity were significantly less than
hose of the Veh-posttest group [pERK: F(1, 20) =
97.09, pCREB: F(1, 20) = 194.19, pElk-1: F(1, 20) =
01.60, Fos: F(1, 20) = 427.93; ps < 0.001; Figure 6B].
dditionally, the numbers of immunoreactive cells ob-
erved following test day 15 were significantly less in
he U0126-posttest compared to Veh-posttest group
pERK: F(1, 25) = 80.36, pCREB: F(1, 25) = 72.16, pElk-
: F(1, 25) = 82.40, Fos: F(1, 25) = 72.35; ps < 0.001,
igure 7B].
To examine localization of pERK-ir with a neuronal
arker, overlap with NeuN-ir was examined in the AcbC
f ten animals from the group infused with the PD98059
eh (Veh-posttest). Of the 112 pERK-ir cells visualized,
05 (93.8%) showed clear NeuN-ir. This indicates that
he majority, if not all, of the pERK-ir cells quantified
ere neuronal.
These results reveal that the MEK inhibitor’s action
n this signaling pathway cannot be explained by an
cute pharmacological effect; instead, it results from
ntagonism of a memory-dependent cascade. The re-
rieval-dependent suppression of the ERK signaling
ascade during subsequent memory tests further sup-
orts the view that activation of the AcbC ERK signaling
ascade underlies cue-elicited COC seeking. Further-
ore, any contribution of the ERK signaling pathway in
cbC nonneuronal cells to the effects observed in these
xperiments appears to be minor.
iscussion
ecent research has attempted to link molecular as-
ects of the neural mechanisms underlying the behav-
oral effects of repeated drug administration and those
esponsible for more traditional forms of learning and
emory. The present findings advance our current
nowledge by demonstrating that inhibition of one in-
racellular signaling cascade during or immediately af-
er retrieval interferes with a classically conditioned
emory for drug-paired contextual cues.
Rats were trained to associate COC treatment with
istinctive environmental cues. Following expression of
OC-CPP in a drug-free state, ERK and two down-
tream transcription factors, CREB and Elk-1, were ac-
ivated, with significantly increased pERK, pCREB, and
Elk-1 levels in the AcbC, but not AcbSh. We previously
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879Figure 7. Effect of Intra-AcbC U0126 Infusions on COC-CPP Re-
consolidation and Concomitant Protein Activation Tested 14 Days
Postinfusion
(A) Test day 1 and 15 difference scores (*Student’s t tests, p < 0.01)
in veh (n = 13) and U0126-infused (n = 14) animals. (B) Quantifica-
tion of AcbC pERK, pCREB, pElk-1, and Fos (*one-way ANOVAs,
p < 0.001) following COC-CPP reconsolidation test. Error bars de-
note SEM.reported that similar training resulted in increased num-
bers of Fos-ir cells in the AcbC, but not AcbSh (Miller
and Marshall, 2005). Through translocation to the nu-
cleus and phosphorylation of CREB and Elk-1, ERK
may regulate c-fos transcription in AcbC neurons dur-
ing COC-CPP expression. Moreover, we observed that
intra-AcbC infusions of two selective MEK inhibitors,
U0126 and PD98059, blocked the retrieval and recon-
solidation of COC-CPP memory, as well as the CPP-
induced increases in the activation of ERK, CREB, Elk-1,
and Fos. Even 2 weeks after pairing the U0126 infusion
with the retrieval test, rats displayed no evidence of
memory for their previous preference. Together, these
findings provide strong evidence for the involvement of
the AcbC ERK signaling pathway in memory for the
COC-CPP task.
Alternative explanations for these behavioral findings
have been considered. The lack of preference in the
MEK inhibitor-infused animals on test day 2 or 15 could
represent accelerated extinction of the COC-CPP
memory. However, this seems unlikely because consoli-
dation of new memories is ERK dependent (Atkins et
al., 1998; Kelly et al., 2003). Because ERK activation
was inhibited in our MEK inhibitor-infused animals, the
interpretation that extinction is accelerated in these an-imals would assume that extinction learning is ERK in-
dependent. Yet, the extinction of fear conditioning has
been shown to be ERK dependent (Cammarota et al.,
2004). In addition, it might be argued that infusion of
U0126 reduces the time spent in the COC-paired cham-
ber by inducing a conditioned place aversion in these
animals. However, the U0126-infused animals exhibited
an equivalent number of entries into the drug-paired
compartment at the initial test and test day 2, suggest-
ing the U0126 infusion on test day 1 did not cause
these animals to avoid the COC-paired compartment.
Also, these animals did not spend less time in the COC-
paired compartment relative to the initial test (Figure
6A), which would have been expected if an aversion
had developed.
While CPP is an excellent model of cue-elicited drug
seeking because of its simplicity, the rapidity with
which drug-paired associations develop, and the resis-
tance of those memories to extinction, certain limita-
tions exist. For instance, with CPP the amount and pat-
tern of drug administration is set by the experimenter,
rather than the animal. An important future extension of
the current findings will be to replicate them in another
model of cue-elicited drug seeking, such as cue-elic-
ited reinstatement of self-administration.
The AcbC Contributes to COC-CPP Memory
The Acb is recognized as important for motivation di-
rected at drug seeking by integrating pertinent informa-
tion from the prefrontal cortex and amygdala and
relaying it to motor output structures. Exposure to
COC-paired cues causes an elevation in Acb neuron
firing rates (Carelli and Ijames, 2001) and extracellular
dopamine (DA) levels (Weiss et al., 2000), as well as
increased levels of Fos (Miller and Marshall, 2004, 2005).
Postconditioning AcbC inactivation disrupts cue-elic-
ited drug seeking (Fuchs et al., 2004), with a study em-
ploying asymmetric hemispheric inactivation under-
scoring the importance of the projection from the BLC
to the AcbC (Di Ciano and Everitt, 2004). Consistent
with this, the current study revealed elevated levels of
activated ERK2, CREB, and Elk-1 in the AcbC, but not
AcbSh, of animals tested for COC-CPP.
Beyond supporting a role for the AcbC in motivation
for drug-paired contextual cues, our findings indicate a
role for this brain region in memory for these associa-
tions. Of special interest is the involvement of AcbC
ERK in both COC-CPP retrieval and reconsolidation.
Blockade of the ERK signaling pathway via MEK inhibi-
tion appears to have two effects within the AcbC. First,
the MEK inhibitor acutely interferes with COC-CPP re-
trieval, preventing cue-elicited drug seeking. Similar
findings have been reported for MEK inhibition of meth-
amphetamine-CPP recall (Mizoguchi et al., 2004). Sec-
ond, and more surprisingly, MEK inhibition within the
AcbC has an enduring effect by blocking reconsolida-
tion of memories for the COC-paired environment, an
effect that lasts for at least 2 weeks. Importantly, the
blockade of a place preference only occurred when the
MEK inhibitor was combined with a COC-CPP test. This
finding indicates (1) that the lack of a place preference
on test day 2 cannot be attributed to residual MEK in-
hibitor still present in the animals’ brains, as U0126-
Neuron
880infused animals not tested on test day 1 (U0126-no test
group) showed normal CPP on test day 2 and (2) that
the U0126 and PD98059 infusions had a lasting amnes-
tic effect (at least 2 weeks postinfusion) only when the
MEK inhibition coincided with memory retrieval.
The discovery of an important role for the ERK signal-
ing pathway in both retrieval and reconsolidation is of
interest. Recently, Winters and Bussey (2005) found
that retrieval and consolidation of object recognition
are similarly impaired by transient inactivation of AMPA
receptors in the perirhinal cortex, but reconsolidation
was not investigated. To our knowledge, the current
study is the first to identify a molecular mechanism that
blocks both retrieval and reconsolidation of any type
of memory.
Role of ERK in Retrieval of COC-CPP Memory
The involvement of the ERK signaling pathway in COC-
CPP raises questions about how this pathway contrib-
utes to memory recall and the modification of synaptic
function underlying drug-cue associations. Many cell
surface receptors couple to the ERK pathway through
a family of small GTPases. Once activated, ERK affects
cellular function in multiple ways, through phosphoryla-
tion of membrane and cytosolic proteins and transcrip-
tional and translational controls (Sweatt, 2001; Kelleher
et al., 2004).
Both AMPA and DA receptor binding are necessary
for COC-CPP, and both receptor types can initiate ERK
activation (Kaddis et al., 1995; Liao et al., 1998; Rober-
son et al., 1999). Therefore, U0126’s acute effects on
CPP may be mediated by inhibition of DA and/or AMPA
receptor-mediated ERK activation in the AcbC. Indeed,
systemic D1 antagonist administration blocks metham-
phetamine-CPP and the accompanying ERK phosphor-
ylation in the Acb (Mizoguchi et al., 2004). Considering
the short time course over which U0126’s effects on
CPP retrieval occur, ERK inhibition may be achieving
its acute effect by preventing ERK’s nontranscriptional
control of cell functioning. Because DAergic action at
D1 and D2 receptors in the Acb is necessary for the
expression of COC-CPP, a blockade of the ERK-depen-
dent phosphorylation of DA’s biosynthetic enzyme,
tyrosine hydroxylase (Lindgren et al., 2002) may be re-
sponsible for the U0126-induced impairment in COC-
CPP retrieval. Alternatively, this drug may block ERK-
dependent phosphorylation of membrane proteins that
control membrane excitability (e.g., the potassium
channel Kv4.2) in AcbC. These channels may be poten-
tial targets for ERK-dependent modulation of mem-
brane excitability in the hippocampus (Birnbaum et
al., 2004).
Role of the ERK Signaling Pathway
in Reconsolidation of COC-CPP Memory
Strikingly, intra-AcbC infusions of U0126 exerted a last-
ing blockade of the retrieval-dependent memory for
COC-CPP, which can be interpreted as interference
with reconsolidation. The posttest U0126 and PD98059
infusions paired with a CPP test on test day 1 both
impaired memory for COC-CPP on test day 2 or 15, a
disruption that likely reflects interference by the MEK
inhibitor with transcription and/or translation at a time
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nhen memory has been recalled and is labile. In sup-
ort of this, we observed that the MEK inhibitor abol-
shed nearly all phosphorylation of ERK, CREB, and
lk-1 as well as the majority of Fos induction 90 min
fter the retrieval test, the time at which reconsolidation
resumably occurs. Animals given the MEK inhibitor
nd not euthanized following the day 1 retrieval test
videnced no place preference when tested again the
ollowing day, suggesting that this MEK/ERK/CREB/
lk-1 signaling pathway is required for the return to
torage of memory for drug-paired cues. This inter-
retation also explains the activation profile of ERK sig-
aling following the tests on days 2 and 15. Compared
o all controls, animals given MEK inhibitor infusions
oupled with CPP memory retrieval on test day 1
howed marked attenuation of ERK, CREB, Elk-1, and
os activation on test day 2 and 15.
econsolidation of Memory for Drug-Paired
ontextual Cues
ince the work of Nader et al. (2000), much has been
ritten concerning the neurobehavioral significance of
etrieval-dependent memory disruption. Disruption of
he retention of apparently stable memories during their
etrieval has been interpreted to indicate either (1) that
he consolidation of these memory traces requires
uch longer (days or weeks) postlearning than gen-
rally assumed (Dudai and Eisenberg, 2004), or (2) that
ven well-established memories can become destabi-
ized during recall as a way to incorporate new informa-
ion into their neural representations (Suzuki et al.,
004; Milekic and Alberini, 2002). While most studies
ave employed protein synthesis inhibitors to interfere
ith recall of fear conditioning, some recent investiga-
ions had demonstrated the involvement of more spe-
ific molecular mechanisms, including protein kinase A,
REB, and zif268 (Koh and Bernstein, 2003; Kida et al.,
002; Bozon et al., 2003; Lee et al., 2004). Two other
tudies implicated ERK in the reconsolidation process
nderlying object recognition memory and fear condi-
ioning (Kelly et al., 2003; Duvarci et al., 2005). The pre-
ent work is the first to identify any molecular mecha-
ism underlying reconsolidation of an aberrant form of
earning: i.e., conditioned stimulus associations in a
odel of drug addiction.
The extended duration (at least 2 weeks) of the inter-
erence with reconsolidation resulting from a single
airing between a MEK inhibitor and CPP retrieval is
articularly noteworthy. Evidence using protein synthe-
is inhibition to interrupt the reconsolidation of fear condi-
ioning suggests that the memory deficit may fade at
onger drug-retest intervals (Lattal and Abel, 2004).
herefore, we repeated the reconsolidation paradigm
ut delayed the second, postinfusion test by 14 days.
ven 2 weeks after the retrieval-infusion test, the MEK
nhibitor animals failed to show CPP or activation of the
RK signaling pathway. Although the present experi-
ental procedures differ in many ways from those em-
loyed by Lattal and Abel (2004), the significance of
he current results arises from their demonstration that
nterference with drug-paired contextual cue memories
eed not be short-lasting.
While much remains to be understood concerning
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881the cellular processes underlying the effects of ERK in
drug-stimulus associations and other types of learning
and memory, the present findings offer hope for treating
cue-elicited relapse in addicts. It is widely accepted
that memories for drug-associated stimuli, which are
strong and resistant to extinction, are responsible for
much of the relapse seen in addicts. The present find-
ings suggest that these highly resistant memories may
again be made labile and thus susceptible to disruption
by pharmacological or other neurobiological interven-
tions, providing opportunities for new therapies.
Experimental Procedures
Animals
All animals were individually housed on a 12 hr light/dark cycle with
ad libitum access to food and water. The housing conditions and
care of the animals were consistent with those specified in the
Guide for the Care and Use of Laboratory Animals (Institute of Lab-
oratory Animal Resources on Life Science, National Research
Council, 1996). All procedures were performed during the light part
of the diurnal cycle. Male Sprague-Dawley rats, weighing 250–275 g
were handled for 5 days prior to behavioral conditioning. Rats to
receive cannula implants weighed 275–300 g and were handled for
2 days prior to surgery.
Place Preference Apparatus
Conditioning took place in a three-chamber apparatus consisting
of two larger compartments (29 cm × 25 cm) separated by a smaller
compartment (11 cm × 25 cm). The two larger compartments had
different visual, tactile, and olfactory cues (see Miller and Marshall,
2004 for details).
Control Environment
In addition to placing animals in the compartments of the condi-
tioning chamber, animals were placed in an alternate environment
for control purposes as described below. The control environment
consisted of a clear plastic cage (27 cm × 48 cm), distinct from the
home cage, located in a room independent of both the CPP appa-
ratus and holding rooms.
Cannula Implantation
Rats undergoing surgery were anesthetized with equithesin and se-
cured in a Kopf stereotaxic apparatus. Bilateral stainless steel
guide cannulae (26G; Plastics One, Roanoke, VA) were aimed at
the AcbC (AP: +1.6 mm relative to bregma; ML: ±2.3 mm; DV: −7.6
mm, from skull; Paxinos and Watson, 1998). Clearance through the
guide cannulae was maintained with 33G obturators (Plastics One)
cut to project 1 mm beyond the tip of the guide. Animals were
habituated to dummy cannula removal and given 5 days of recov-
ery and handling before the start of behavioral conditioning.
Drugs
U0126 (Promega, Madison, WI) was dissolved in 5% DMSO and
6% Tween 80 and diluted to a concentration of 2 g/l in 0.1 M
phosphate-buffered sal (PBS). PD98059 (Calbiochem, Dartmstadt,
Germany) was dissolved in 20% DMSO and 20% Tween 80 and
diluted to a concentration of 4 g/l with 0.9% sal. Control animals
received equal volume intra-AcbC infusions of the veh or 0.9% sal
solutions to ensure that the veh itself had no behavioral or neuro-
chemical effects.
Behavioral Conditioning
Baseline preferences were assessed by placing the animals in the
center compartment of the place preference apparatus and allow-
ing free access to all compartments for 15 min. Time spent in each
compartment was recorded. Because a Wilcoxon signed ranks test
revealed no significant overall preference for either large compart-
ment initially, we arbitrarily paired the COC injections with the
checkered compartment. Conditioning took place over the next 9
days. The animals were divided into a drug-paired and a drug-unpaired group, such that each group had an equal mean initial
time spent in each compartment. The drug-unpaired group served
as a control for history of COC administration. These animals re-
ceived amounts of COC-HCl (10 mg/kg, i.p.; Sigma) equal to those
administered to the drug-paired animals, but given in the control
environment and sal (1 ml/kg, i.p.) prior to placement in each of the
CPP compartments. Removable partitions were put in place for the
conditioning days, confining animals to a specific compartment for
30 min. A counterbalanced design was used so that half of the
drug-paired animals were given COC prior to placement in the
checkered compartment on the first day, and half received sal prior
to placement in the white compartment (for further details, see
Miller and Marshall, 2004). Forty-eight hours after the last condi-
tioning session, preference was assessed as previously described.
A difference score was calculated by subtracting the time spent in
the COC-paired compartment at baseline from time spent during
the final test.
Animals to receive intra-AcbC infusions were divided into three
groups (U0126, veh, or sal infusion) after initial testing. Because a
Wilcoxon signed ranks test revealed no significant overall prefer-
ence for either compartment initially, we arbitrarily chose to pair
the COC injections with the white compartment. For these experi-
ments, the control environment was not used. The behavioral con-
ditioning consisted of three COC pairings, alternated with three sal
pairings over 6 days. Thirty minutes prior to or immediately after
the final place preference testing, animals were given an intra-
AcbC infusion of 0.5 l of sal, veh, or U0126 (1 g) over 2 min
(U0126 infusion time and dose based on Kelly et al., 2003, Schafe
et al., 2000, and Hebert and Dash, 2004). Injectors remained in
place for 1 min after drug infusion. The remaining animals were
given the same intra-AcbC infusions of U0126, veh, or sal but were
not tested for a place preference. Half of the animals given infu-
sions and tested for their place preference on test day 1 were per-
fused 90 min later. The other half of the animals were returned to
their home cage after the preference test. The following day, test
day 2, these same animals, as well as the animals that received
infusions but no CPP test on test day 1, were tested for their pref-
erence.
In a separate experiment, animals to receive intra-AcbC infusions
were divided into two groups (PD98059 or veh infusion) after initial
testing. The behavioral conditioning was identical to the previous
experiment. Immediately after the final place preference testing,
animals were given an intra-AcbC infusion of 0.5 l of veh or
PD98059 (2 g) over 2 min (PD98059 dose based on Gerdjikov et
al., 2004 and Mizoguchi et al., 2004). The following day, test day 2,
these same animals were again tested.
In a similar experiment, animals to receive intra-AcbC infusions
were divided into two groups (U0126 or veh infusion) after initial
testing. Immediately after the final place preference testing, ani-
mals were given an intra-AcbC infusion of 0.5 l of veh or U0126
(1 g) over 2 min and returned to their home cage. Fourteen days
later, test day 15, these same animals were again CPP tested.
Tissue Preparation for Western Blotting
Half of the rats that did not receive intra-AcbC infusions were eu-
thanized by decapitation 15 min after the end of the final CPP test.
The 15 min posttest survival time was chosen based on the phos-
phorylation kinetics of these proteins reported by several groups
(Choe and McGinty, 2001; Valjent et al., 2000; Zhang et al., 2004).
Their brains were quickly removed and frozen in isopentane (−20°C)
for approximately 2 min, after which they were stored at −80°C.
AcbC and AcbSh (+1.6 mm relative to bregma; Paxinos and Wat-
son, 1998) punches were obtained with a 1 mm punch tool (Zivic
Laboratories, Inc., Pittsburgh, PA) from 1 mm thick sections taken
on a sliding freezing microtome (see Figure 2B).
Tissue Preparation for ICC
Half of the rats that did not receive intra-AcbC infusions were eu-
thanized 15 min after completion of the final CPP test, while rats
that received intra-AcbC infusions were euthanized 90 min after
completion of their respective final CPP test. All animals were
deeply anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and
transcardially perfused with ice-cold 0.1 M phosphate-buffered sal
Neuron
882(PBS) (pH 7.4), followed by ice-cold 4% paraformaldehyde in PBS
(pH 7.4), with 0.1 mM NaF. The brains were removed, post fixed
overnight at 4°C, and then transferred to 30% sucrose for 48 hr at
4°C. Coronal sections (40 m) were collected at the level corre-
sponding to Acb using a freezing microtome. One set of tissue from
rats that received intra-AcbC infusions was stained with cresyl vio-
let to verify the location of the infusion needle tips.
Western Blotting
Punches were sonicated in 60 l of ice-cold lysis buffer (150 mM
NaCl, 50 mM NaF, 10 mM β-glycerol, 20 mM HEPES [pH 7.4], 1%
Triton X-100, and 1× Halt protease inhibitor cocktail, EDTA-free).
Laemmli buffer was added to the homogenates, and the samples
were boiled at 95°C for 10 min. Homogenates containing 5 g of
protein from either the AcbC or AcbSh were electrophoresed on
4%–20% SDS-polyacrylamide gels and blotted to 0.2 m nitrocel-
lulose membranes. Western blots were first incubated with anti-
bodies to pERK, pCREB, and pElk-1. Blots intended for pERK and
pElk-1 antibodies were blocked in Tris-buffered sal with Tween
(TBST; 100 mM Tris-HCl [pH 7.6], 150 mM NaCl, and 0.1% Tween
20) and 5% milk. Blots intended for the pCREB antibody were
blocked in TBST with 5% bovine serum albumin (BSA; Sigma).
Blots were then incubated with an anti-phospho-p44/42 MAPK
(pERK) rabbit polyclonal antibody (1:20,000; #9101, Cell Signaling,
Beverly, MA), anti-phospho-CREB rabbit polyclonal antibody
(1:1000; #9191, Cell Signaling), or anti-phospho-Elk-1 mouse
monoclonal antibody (1:2000; #sc-8406, Santa Cruz Biotechnology,
Inc., Santa Cruz, CA) overnight at 4°C (pERK, pCREB) or at room
temperature (RT) overnight (pElk-1). Blots were then incubated with
anti-rabbit (pERK and pCREB) or anti-mouse (pElk-1) secondary
antibody conjugated to horseradish peroxidase (HRP; 1:10,000;
Vector Laboratories; Burlingame, CA) and developed using en-
hanced chemiluminescence (SuperSignal West Pico Chemilumi-
nescent substrate; Pierce, Rockford, IL). All blots were then incu-
bated in anti-cyclophilin rabbit polyclonal antibody (1:20,000;
#07-313, Upstate, Lake Placid, NY) with TBST and 5% milk over-
night at 4°C. Blots were then incubated with anti-rabbit secondary
antibody conjugated to HRP (1:10,000) and developed using en-
hanced chemiluminescence. All blots were then incubated in Re-
store Western Blot Stripping Buffer (Pierce) for 15 min at RT to
remove the antibodies directed at the phosphoproteins and allow
for binding of antibodies directed at the nonactive form of the pro-
teins. Blots were incubated in anti-MAPK (ERK) rabbit polyclonal
antibody (1:10,000; #9102, Cell Signaling), anti-CREB rabbit poly-
clonal antibody (1:1000; #9192, Cell Signaling), or anti-Elk-1 rabbit
polyclonal antibody (1:1000; #sc-355, Santa Cruz Biotechnology,
Inc.) with TBST and 5% milk (ERK and Elk-1) or TBS (no Tween)
and 5% BSA (CREB) overnight at 4°C (pERK, pCREB) or at RT over-
night (pElk-1). Blots were then incubated with anti-rabbit secondary
antibody conjugated to HRP (1:10,000) and developed using en-
hanced chemiluminescence.
ICC
Serial coronal sections through Acb were processed for pERK,
pElk-1, and pCREB-ir from animals tested for CPP expression and
pERK, pElk-1, pCREB, and Fos-ir from animals given intra-AcbC
infusions and tested for CPP retrieval or reconsolidation.
Sections processed for pERK were rinsed in 0.3% H2O2. All sub-
sequent solutions were made in 0.1 M TBS with 0.1% Triton X-100
(Sigma) (TBS/TX). Tissue was incubated with 3% BSA for 1 hr, then
overnight at 4°C with anti-phospho-p44/42 MAP kinase rabbit poly-
clonal antibody (1:2000, Cell Signaling). Sections were rinsed and
incubated with biotinylated goat anti-rabbit immunoglobulin G (IgG)
(1:200; Vector) and 1% BSA for 1 hr, then rinsed and incubated with
avidin-biotinylated peroxidase complex (ABC Elite kit; Vector) for
1 hr. The reaction was terminated by rinsing twice in TBS/TX
and once in TBS. The tissue was then incubated in a 1:1 dilution
of nickel-enhanced diaminobenzidine tetrahydrochloride (Ni-DAB,
purple/black reaction product; Vector) for 5 min, then rinsed in
0.1 M Tris buffer (pH 7.4). Sections were mounted onto gelatin-
coated slides, dried, and dehydrated (95% then 100% EtOH for 5
min each) before coverslipping.
pElk-1 ICC was performed as described for pERK with the fol-
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aowing exceptions. All solutions were made in 0.05 M TBS/Tween
0 with 0.1 mM NaF. Tissue was incubated for 48 hr at 4°C, with
he first hour of incubation performed at RT, in anti-phospho-Elk-1
ouse monoclonal antibody (1:1000; #9186, Cell Signaling). The
econdary antibody was a biotinylated goat anti-mouse IgG
1:200; Vector).
pCREB ICC was performed as described for pERK with the fol-
owing exceptions. All solutions were made in 0.1 M PBS with 0.1
M NaF. Sections were incubated for 24 hr at RT with anti-phos-
ho-CREB rabbit polyclonal antibody (1:5000; #06-519, Upstate).
Fos ICC was performed as described for pERK with the following
xceptions. All solutions for Fos ICC were made in 0.1 M PBS. Sec-
ions were incubated for 48 hr at 4°C with anti-Fos rabbit polyclonal
ntibody (1:15,000; PC-38, Oncogene Science, Cambridge, MA).
To evaluate the neuronal-specific pERK antibody labeling, a sub-
et of AcbC sections from ten animals infused with the veh for
D98059 were processed for pERK and NeuN double immunofluo-
escence. Sections were treated as described above for pERK-ir,
xcept that the antibody concentration was 1:200 and the sections
ere incubated at RT overnight. Instead of ABC and Ni-DAB, the
ections were incubated with avidin-bound Fluorescein (20 g/ml;
ector) for 2 hr. The tissue was then incubated in PBS containing
% BSA for 1 hr, followed by incubation overnight at RT with anti-
euronal nuclei (NeuN) mouse monoclonal antibody (1:500;
MAB377, Chemicon). The sections were incubated in avidin-
ound Rhodamine (20 g/ml; Vector) for 2 hr. Sections were rinsed
n Tris, mounted, dried overnight, dipped in xylene, and cover-
lipped using Fluoromount.
estern Blot Analysis
estern blots were developed in the linear range used for densi-
ometry. Densitometry was conducted using MCID image analysis
oftware. To assess changes in the activation of ERK1, ERK2,
REB, and Elk-1, activated kinase levels were normalized both to
evels of the respective kinases as well as to cyclophilin, which was
sed as a loading control protein.
mmunoreactivity Quantification
istributions of pERK-ir cells were studied by viewing the tissue
ith an Olympus microscope at 100× magnification. All pERK-ir
ells were counted manually. For quantification of pCREB, pElk-1,
nd Fos-ir, the microscope was attached to an MCID image analy-
is system (Imaging Research Inc., ON, Canada). pCREB, pElk-1,
nd Fos-ir nuclei were imaged at 100× and differentiated from
ackground based on optical density and size criteria established
y the experimenter’s visual identification of these cells. For each
nimal, cells were quantified in both hemispheres of three sections,
nd the counts were averaged to give a mean number of each
mmunoreactive cell type per mm2.
To analyze the extent of pERK-ir overlap with the neuronal
arker NeuN within the AcbC, sections were digitized under 100×
agnification. Images of pERK-ir AcbC cells were collected using
ilters for Fluorescein (Leica L5; Ex = 495–500 nm). Images of NeuN-
r AcbC cells were collected using filters for Rhodamine (Leica Y3;
x = 550–560 nm). pERK-ir neurons were then assessed for their
verlap with NeuN-ir.
tatistical Analysis
he experimenter was blind to treatment groups when taking all
easures. For experiments conducted on cannulated rats, only an-
mals in which the tips of the infusion needles were located within
he AcbC were included in the analyses (Figure 3).
CPP, ICC, and Western blot data derived from comparing drug-
aired and unpaired groups (Figures 1A and 1B; Figures 2A and
B) were analyzed by mixed factor ANOVA, with drug pairing as a
etween-subjects factor and test session or Acb regions as a
ithin-subjects factor. Data from ICC or Western blotting of each
hosphoprotein were analyzed separately. When significant group
y test or region interactions occurred, specific comparisons be-
ween initial and final CPP scores were made using a Wilcoxon
igned ranks test, while specific comparisons between drug-paired
nd unpaired groups were made using Student’s t tests.
Effects of U0126 on CPP retrieval (Figure 4A) were subjected to
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883the same mixed-factor ANOVA, in which infusion (veh versus
U0126) was a between-subjects factor and test session was a
within-subjects factor. Separate one-way ANOVAs were used to
compare these two groups for CPP difference scores, locomotor
measures, and immunoreactivity (Figures 4B and 4C).
Effects of U0126 on CPP reconsolidation and accompanying im-
munoreactivity (Figures 5A and 5B) were analyzed by 2 × 2 (for test
day 1 CPP scores) or 3 × 2 (for test day 2 CPP scores and ICCs)
ANOVAs. In each analysis, intra-AcbC drug treatment (veh versus
U0126) and infusion time were between-subject factors. Significant
interactions between drug treatment and infusion time were ob-
served for each of the 3 × 2 ANOVAs.
Orthogonal comparisons were then conducted on the significant
interactions observed in the 3 × 2 ANOVAs to test whether (1) the
“no test” groups differed from the “pretest” and “posttest” groups,
and (2) the “pretest” and “posttest” groups differed. Selected spe-
cific group comparisons were made using Student’s t tests.
CPP data for the PD98059 and U0126 15 day experiments (Fig-
ures 6A and 7A) were also analyzed using two-way factorial ANO-
VAs, in which intra-AcbC infusion type (veh versus MEK inhibitor)
was a between-subjects factor and test day was a within-subjects
factor. Specific comparisons between MEK inhibitor and veh-
infused groups were made using Student’s t tests for each of the
test days. ICC data from each region of those experiments (Figures
6B and 7B) were analyzed by one-way ANOVAs.
Bonferroni corrections were used for all Student’s t tests and
one-way ANOVAs.
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